DualPhos

DualPhos is a biopharmaceutical company headquartered in Geneva, Switzerland, that specializes in the development of phosphonate-based therapeutics. Founded in 2014 by Dr. Elena Vasilev and Dr. Marcus Lee, the firm focuses on designing dual-function phosphonate molecules that can simultaneously inhibit viral replication and modulate host immune responses. The company’s flagship product, DP-01, is a nucleotide analogue with a phosphonate backbone engineered to enhance metabolic stability and reduce toxicity compared to traditional phosphates.

The DualPhos research pipeline includes antiviral agents targeting RNA viruses such as influenza, dengue, and emerging coronavirus strains. In addition, the company is exploring dual‑target drugs for metabolic disorders, where phosphonate groups act as inhibitors of key enzymes in lipid and bile acid biosynthesis. DualPhos’ technology platform is built on a proprietary synthetic route that allows for the rapid assembly of branched phosphonate scaffolds, enabling high-throughput screening of compound libraries.

In 2020, DualPhos entered a collaboration with the World Health Organization to support the discovery of broad‑spectrum antivirals. By 2022, the company initiated a Phase I clinical trial of DP-01 for severe flu infection, reporting no severe adverse events in the first cohort of 30 participants.

Beyond drug development, DualPhos engages in academic partnerships to investigate the role of phosphonate chemistry in RNA editing and epigenetic regulation. The company is listed on the Swiss SIX Stock Exchange under the ticker DPHOS. Its mission emphasizes the creation of therapeutics that combine potency with a favorable safety profile, aiming to address unmet medical needs worldwide.